Neovacs obtains FDA approval to extend its Phase IIb clinical trial in Lupus to United States

Paris and Boston, April 28th, 2016 – Neovacs (Alternext Paris: ALNEV)a leader in active immunotherapy for the treatment of autoimmune diseases, today announced that the Company has received the approval “Investigational New Drug” (IND), from the Food and Drug Administration (FDA), to extend its ongoing Phase IIb clinical trial of IFNα Kinoid for the treatment of Lupus to the United States.